The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies

Published on Jun 1, 2021in United European gastroenterology journal3.549
· DOI :10.1002/UEG2.12094
Neeraj Narula23
Estimated H-index: 23
(McMaster University),
Achuthan Aruljothy3
Estimated H-index: 3
(McMaster University)
+ 4 AuthorsWalter Reinisch100
Estimated H-index: 100
(Medical University of Vienna)
This post hoc analysis of the UNITI studies found ustekinumab (UST) did not significantly improve overall extraintestinal manifestations (EIMs) of Crohn's disease compared to placebo-treated patients at weeks 6 and 52. BACKGROUND AND AIMS The UNITI trials demonstrated that UST was effective in inducing and maintaining clinical remission in Crohn's disease (CD). However, limited data exists regarding its effectiveness for treatment of EIMs. This post hoc analysis evaluated the efficacy of UST in treatment of EIMs. METHODS Data from UNITI-1/2 and IM-UNITI (NCT01369329, NCT01369342, NCT01369355) were obtained from the Yale Open Data Access Project (2019-4104). Nine hundred and fourty-one patients eligible for UST induction and 263 patients eligible for maintenance UST were included. The primary outcome of interest was EIM resolution at Week 6 in UST and placebo-treated patients using the chi-square test. EIM resolution at Week 52 was also assessed. McNemar's test was used to compare the proportion of patients who reported active EIMs at weeks 6 and 52 versus baseline. RESULTS From 941 UST-treated patients in UNITI-1/2, 504 had 527 EIMs at baseline. Overall, there was no significant difference in EIM resolution observed in UST-treated patients (186/504, 36.9%) compared to placebo (90/230, 39.1%; p = 0.564) at Week 6. Patients treated with continuous UST (91/119, 76.4%) had no significant difference in overall EIMs resolved at Week 52 compared to placebo (72/90, 80.0%; p = 0.542). Although many EIMs demonstrated reduction in prevalence compared to baseline at initiation of UST, only erythema nodosum was more likely to improve at Week 52 on treatment versus placebo. CONCLUSION Overall, UST did not lead to significant resolution of EIMs for CD compared to placebo at weeks 6 and 52.
#1Lucas Guillo (University of Lorraine)H-Index: 1
#2Ferdinando D'Amico (Humanitas University)H-Index: 14
Last. Laurent Peyrin-Biroulet (University of Lorraine)H-Index: 103
view all 4 authors...
BACKGROUND AND AIMS Extraintestinal manifestations (EIMs) are frequent in patients with inflammatory bowel diseases (IBD) and a challenging condition to manage. Tumor necrosis factor alpha antagonists (anti-TNFα) are recognized as the primary therapeutic option. We aimed to summarize evidence on the efficacy of ustekinumab for the treatment of EIMs. METHODS We searched in PubMed, Cochrane Library, and Web of Science up to October 2020 all interventional and non-interventional studies published i...
#1Alka Goyal (Children's Mercy Hospital)H-Index: 8
#2Yuhua Zheng (Children's Hospital Los Angeles)H-Index: 1
Last. Andrew B. Grossman (Children's Hospital of Philadelphia)H-Index: 16
view all 11 authors...
Anemia is one of the most common extraintestinal manifestations of inflammatory bowel disease (IBD). It can be asymptomatic or associated with non-specific symptoms such as irritability, headaches, fatigue, dizziness and anorexia. In IBD patients, the etiology of anemia is often multifactorial. Various causes include iron deficiency, anemia of inflammation and chronic disease, vitamin deficiencies, hemolysis, or myelosuppressive effect of drugs. Anemia and iron deficiency in these patients may b...
2 CitationsSource
#1Ciro RomanoH-Index: 22
#2Sergio EspositoH-Index: 2
Last. Giovanna CuomoH-Index: 27
view all 4 authors...
ABSTRACTIntroduction: approximately half of Crohn’s disease (CD) patients suffer from concomitant extra-intestinal manifestations (EIMs). Moreover, CD patients may suffer from comorbidities or have...
2 CitationsSource
#1Sana Chams (Beaumont Health)H-Index: 5
#1Sana Chams (Beaumont Health)H-Index: 2
Last. Inaya Hajj Hussein (Oakland University)H-Index: 10
view all 6 authors...
Inflammatory bowel disease is a chronic inflammatory condition that encompasses Crohn’s disease and ulcerative colitis. Inflammatory bowel disease is not exclusive to the gastrointestinal system, a...
5 CitationsSource
#1Thomas Greuter (UZH: University of Zurich)H-Index: 17
#2Stephan R. Vavricka (UZH: University of Zurich)H-Index: 43
ABSTRACTIntroduction: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, primarily of, but not restricted to the gut. Extraintestinal manifestations (EIMs) are frequently observed and involve the joints, eyes, hepatobiliary tract, and skin.Areas covered: In this review, we discuss classical EIM focusing on epidemiology, genetics, and pathogenesis, highlighting recent advances in the understanding of EIM. We further discuss treatment-induced immunological phenomena, which are in...
20 CitationsSource
#1Frank M Phillips (Katholieke Universiteit Leuven)H-Index: 1
#2Bram Verstockt (Katholieke Universiteit Leuven)H-Index: 20
view all 14 authors...
: This was a multicentre case series supported by the European Crohn's and Colitis Organisation (ECCO) and, performed as part of the Collaborative Network of Exceptionally Rare case reports (CONFER) project. The aim was to report on whether cutaneous lesions associated with inflammatory bowel disease (IBD) and refractory to standard medical therapy including anti-TNFs, would respond to the newer biologic agents Ustekinumab (UST) or Vedolizumab (VDZ). This report includes 28 patients with cutaneo...
8 CitationsSource
#1Kathryn L. Pepple (UW: University of Washington)H-Index: 13
#2Phoebe Lin (OHSU: Oregon Health & Science University)H-Index: 24
The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn’s disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies...
19 CitationsSource
#1Chung Sang Tse (Mayo Clinic)H-Index: 9
#2Edward V. Loftus (Mayo Clinic)H-Index: 114
Last. Amy L. Lightner (Mayo Clinic)H-Index: 20
view all 5 authors...
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic biliary disease associated with inflammatory bowel disease (IBD) with no known cure. AIM: To evaluate the effect of biological therapies on PSC progression in IBD patients. METHODS: We performed a retrospective cohort study of 88 cases (75 unique patients with 12 patients treated >1 biologics) of IBD (48 ulcerative colitis, 24 Crohn's disease and 3 indeterminate colitis) with concomitant PSC who received biolo...
27 CitationsSource
#1Edouard LouisH-Index: 37
#2Walter Reinisch (Medical University of Vienna)H-Index: 100
Last. Brandee Pappalardo (AbbVie)H-Index: 5
view all 10 authors...
Introduction Extraintestinal manifestations (EIMs) in patients with Crohn’s disease (CD) are common and associated with additional morbidity. This study aimed to evaluate the effect of adalimumab therapy on EIM resolution and identify potential predictors of EIM resolution in adult and pediatric patients with moderate to severe CD.
8 CitationsSource
#1Carolina PalmelaH-Index: 10
#2Farhad Peerani (U of A: University of Alberta)H-Index: 5
Last. Steven H. Itzkowitz (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 74
view all 5 authors...
: Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic disease that is associated with inflammatory bowel disease (IBD) in approximately 70% of cases. Although the pathogenesis is still unknown for both diseases, there is increasing evidence to indicate that they share a common underlying predisposition. Herein, we review the epidemiology, diagnosis, disease pathogenesis, and specific clinical features of the PSC-IBD phenotype. Patients with PSC-IBD have a distinct IBD phen...
34 CitationsSource
Cited By2